Canada Markets closed

Graphite Bio, Inc. (GRPH)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.0600+0.0900 (+2.27%)
At close: 04:00PM EDT
4.2600 +0.20 (+4.93%)
After hours: 06:00PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • J
    Cash balance is higher than market cap. If there was anything out there worth something at this company, big pharma would have bought it. That makes me guess it could get bought out by a PE shop and then dissolved for cash proceeds.
  • R
    Filled $20.90 for 150 shares.
  • R
    Out of GRPH @ $26.
  • R
    Nice- this is in one week- close to $11 return per share.
  • R
    Secondary offer - to take advantage of NTLA news.
  • A
    bought in at 8.4
  • R
    $NTLA conversation
    Varro Analytics
    Last time there was major #CRISPR headline, $BEAM was still at $28... now $114

    This morning premarket on $NTLA ex vivo ATTR data:

    $NTLA +60%
    $BEAM +20%
    $EDIT +19%
    $CRSP +14%
    $VERV +20%
    $GRPH +16% (was down on Fri IPO day into close)

    Other ATTR therapies

    $ALNY -10%
    $BBIO flat
  • d
    Just so you all know , HDR is very unreliable and won’t correct enrough cells to have a therapeutic effect
  • c
    Found this one on Barron's as a cash rich beaten down bio. In at 2.33 yesterday.
  • R
    $BEAM conversation
    Anybody here has an opinion about GRPH- This is their pitch:

    Varro Analytics
    Replying to
    $GRPH is ONLY co to directly replace #SickleCell disease-causing mutation

    Others work indirectly to compensate by:

    a). Adding transgenic hemoglobin
    b). Reactivating fetal form ( $CRSP $EDIT $NTLA indel knockout)
    c). Changing mutation to new one ( $BEAM #baseediting)

    they also say they are the next generation of gene editing company.
  • G
    G Little
    @rv why are we up 9% AH?
  • T
    The Queen of England
    I can see this going to 50 quick
  • Y
    Yahoo Finance Insights
    Graphite Bio is down 9.06% to 10.09
  • O
    I don't see it is tradable
  • R
    Graphite utilizes Cas9/Recombinant DNA
  • B
    Barney Frank
    A lllonnggg way from a safe and effective product. Lead candidate could hit unforeseen obstacles from compensatory mechanisms, yet unaccounted. Watch list, neutral.
  • R
    $BEAM conversation
    July 1st Short Positions- did a lot of damage to those who looked at paper losses and sold!

    CRSP DNA Retweeted
    Andrew Kernytsky
    Jul 1
    Got curious and pulled the current short interest (% of float) for some CRISPR and gene therapy stocks:
    $EDIT 15.3%
    $BEAM 14.9%
    $DTIL 11.8%
    $SGMO 11.5%
    $NTLA 10.0%
    $BLUE 8.1%
    $CRSP 5.3%
    $GRPH n/a
    $VERV n/a
  • D
    BTD and worth more than cash on the books. Plenty of cash for a couple years. Why trading so low? Insiders have bought a s-ton and sold nothing.
  • A
    $GRPH $27 BY EOD
  • o
    $10 is coming very soon, Just Hold couple days more my fellows